Update in treatment of early breast cancer in post-menopausal women

References

• Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon (France): Ed. International Agency for Research on Cancer; 2013.
   Google Scholar
• Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359(9324):2131–2139.
   PubMed Web of Science ®Google Scholar
• BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. New England J Med. 2009;361(8):766–776.
   PubMed Web of Science ®Google Scholar
• Amir E, Seruga B, Freedman O, et al. Amenorrhoea, menopause, and endocrine therapy for breast cancer. BMJ. 2009;339:b4261.
   PubMed Web of Science ®Google Scholar
• Smith IE, Dowsett M, Yap Y-S, et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol. 2006;24(16):2444–2447.
   PubMed Web of Science ®Google Scholar
• Krekow LK, Hellerstedt BA, Collea RP, et al. Incidence and predictive factors for recovery of ovarian function in amenorrheic women in their 40s treated with letrozole. J Clin Oncol. 2016. [Epub ahead of print].
   PubMedGoogle Scholar
• Bellet M, Gray KP, Francis PA, et al. Twelve-month estrogen levels in premenopausal women with hormone receptor–positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy. J Clin Oncol. 2016. [Epub ahead of print].
   Web of Science ®Google Scholar
• Clemons M, Simmons C. Identifying menopause in breast cancer patients: considerations and implications. Breast Cancer Res Treat. 2007;104(2):115–120.
   PubMed Web of Science ®Google Scholar
• Overlie I, Moen MH, Morkrid L, et al. The endocrine transition around menopause - a five years prospective study with profiles of gonadotropines, estrogens, androgens and SHBG among healthy women. Acta Obstet Gynecol Scand. 1999;78(7):642–647.
   PubMed Web of Science ®Google Scholar
• Ingle JN, Buzdar AU, Schaid DJ, et al. Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res. 2010;70(8):3278–3286.
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262–1271.
   PubMed Web of Science ®Google Scholar
• Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–816.
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(19):1793–1802.
   PubMed Web of Science ®Google Scholar
• Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the national surgical adjuvant breast and bowel project B-14 randomized trial. J Natl Cancer Inst. 2001;93(9):684–690.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Schnabel CA, Schroeder BE, et al. Breast cancer index identifies early-stage estrogen receptor–positive breast cancer patients at risk for early- and late-distant recurrence. Clin Cancer Res. 2013;19(15):4196–4205.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Dowsett M, Forbes JF, et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–1352.
   PubMed Web of Science ®Google Scholar
• Gray RG, Rea D, Handley K, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. ASCO Meet Abstr. 2013;31(15_suppl):5.
   Google Scholar
• Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. J Natl Cancer Inst. 1996;88(24):1828–1833.
   PubMedGoogle Scholar
• Stewart HJ, Prescott RJ, Forrest APM. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst. 2001;93(6):456–462.
   PubMedGoogle Scholar
• Al-Mubarak M, Tibau A, Templeton AJ, et al. Extended adjuvant tamoxifen for early breast cancer: a meta-analysis. PLoS ONE. 2014;9(2):e88238.
   PubMed Web of Science ®Google Scholar
• Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004;5(6):607-616.
   Google Scholar
• Sgroi DC, Carney E, Zarrella E, et al. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst. 2013;105(14):1036–1042.
   PubMedGoogle Scholar
• Sgroi DC, Sestak I, Cuzick J, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. 2013;14(11):1067–1076.
   PubMed Web of Science ®Google Scholar
• Wolmark N, Mamounas EP, Baehner FL, et al. Recurrence score and quantitative ER expression to predict in late distant recurrence risk in ER+ BC after 5 years of tamoxifen. ASCO Meet Abstr. 2014;32(15_suppl):11024.
   Google Scholar
• Sestak I, Dowsett M, Zabaglo L, et al. Factors predicting late recurrence for estrogen receptor–positive breast cancer. J Natl Cancer Inst. 2013;105(19):1504–1511.
   PubMedGoogle Scholar
• Dowsett M, Sestak I, Lopez-Knowles E, et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 2013;31(22):2783–2790.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Coleman R, Powles T, et al. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386(10001):1353–1361.
   PubMed Web of Science ®Google Scholar
• Diel IJ, Jaschke A, Solomayer EF, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow—a long-term follow-up. Ann Oncol. 2008;19(12):2007–2011.
   PubMed Web of Science ®Google Scholar
• Powles T, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res. 2006;8(2):R13.
   PubMed Web of Science ®Google Scholar
• Coleman R, Cameron D, Dodwell D, et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol. 2014;15(9):997–1006.
   PubMed Web of Science ®Google Scholar
• Coleman R, De Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013;24(2):398–405.
   PubMed Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011;12(7):631–641.
   PubMed Web of Science ®Google Scholar
• Paterson AHG, Anderson SJ, Lembersky BC, et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol. 2012;13(7):734–742.
   PubMed Web of Science ®Google Scholar
• Saarto T, Blomqvist C, Virkkunen P, et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol. 2001;19(1):10–17.
   PubMed Web of Science ®Google Scholar
• Von Minckwitz G, Möbus V, Schneeweiss A, et al. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol. 2013;31(28):3531–3539.
   PubMed Web of Science ®Google Scholar
• Gralow J, Barlow WE, Paterson AHG, et al. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: comparison of toxicities and patient-stated preference for oral versus intravenous delivery. J Clin Oncol. 2014;32(5s):suppl; abstr 558.
   Google Scholar
• Gnant M, Pfeiler G, Dubsky P et al. The impact of adjuvant denosumab on disease-free survival: Results from 3,425 postmenopausal patients of the ABCSG-18 trial. In: San Antonio Breast Cancer Symposium; Ed., San Antonio (TX); 2015.
   Google Scholar
• Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103(17):1299–1309.
   PubMed Web of Science ®Google Scholar
• Hu FB, Grodstein F, Hennekens CH, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med. 1999;159(10):1061–1066.
   PubMedGoogle Scholar
• Patnaik J, Byers T, DiGuiseppi C, et al. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 2011;13(3):R64.
   PubMed Web of Science ®Google Scholar
• Mondul AM, Rodriguez C, Jacobs EJ, et al. Age at natural menopause and cause-specific mortality. Am J Epidemiol. 2005;162(11):1089–1097.
   PubMed Web of Science ®Google Scholar
• Savji N, Rockman CB, Skolnick AH, et al. Association between advanced age and vascular disease in different arterial territories. J Am Coll Cardiol. 2013;61(16):1736–1743.
   PubMed Web of Science ®Google Scholar
• Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population. Am Heart J. 1986;111(2):383–390.
   PubMed Web of Science ®Google Scholar
• Bardia A, Arieas E, Zhang Z, et al. Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Res Treat. 2012;131(3):907–914.
   PubMed Web of Science ®Google Scholar
• Christiansen P, Bjerre K, Ejlertsen B, et al. Mortality rates among early-stage hormone receptor–positive breast cancer patients: a population-based cohort study in Denmark. J Natl Cancer Inst. 2011;103(18):1363–1372.
   PubMedGoogle Scholar
• Nelson HD, Pappas M, Cantor A, et al. Harms of breast cancer screening: systematic review to update the 2009 U.S. preventive services task force recommendationharms of breast cancer screening. Ann Intern Med. 2016;164(4):256–267.
   PubMed Web of Science ®Google Scholar
• Wang S-Y, Long JB, Killelea BK, et al. Preoperative breast magnetic resonance imaging and contralateral breast cancer occurrence among older women with breast cancer. J Clin Oncol. 2016;34(4):321–328.
   PubMedGoogle Scholar
• Water W, Bastiaannet E, Scholten A, et al. Breast-conserving surgery with or without radiotherapy in older breast patients with early stage breast cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2014;21(3):786–794.
   PubMed Web of Science ®Google Scholar
• Kunkler IH, Williams LJ, Jack WJL, et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16(3):266–273.
   PubMed Web of Science ®Google Scholar
• Liu -F-F, Shi W, Done SJ, et al. Identification of a low-risk luminal a breast cancer cohort that may not benefit from breast radiotherapy. J Clin Oncol. 2015;33(18):2035–2040.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. New England J Med. 2015;373(21):2005–2014.
   PubMed Web of Science ®Google Scholar
• Partridge AH, LaFountain A, Mayer E, et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26(4):556–562.
   PubMed Web of Science ®Google Scholar
• Partridge AH, Wang PS, Winer EP, et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21(4):602–606.
   PubMed Web of Science ®Google Scholar
• Barron TI, Connolly R, Bennett K, et al. Early discontinuation of tamoxifen. Cancer. 2007;109(5):832–839.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a Cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28(27):4120–4128.
   Web of Science ®Google Scholar
• Breast International Group (BIG) 1–98 Collaborative Group1, Thürlimann B, Keshaviah A, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New England J Med. 2005;353(26):2747–2757.
   PubMed Web of Science ®Google Scholar
• Guttuso T Jr, Kurlan R, McDermott MP, et al. Gabapentin’s effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2003;101(2):337–345.
   PubMed Web of Science ®Google Scholar
• Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet. 2005;366(9488):818–824.
   PubMed Web of Science ®Google Scholar
• Evans MLMD, Pritts EMD, Vittinghoff EPMPH, et al. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol. 2005;105(1):161–166.
   PubMed Web of Science ®Google Scholar
• Bordeleau L, Pritchard KI, Loprinzi CL, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol. 2010;28(35):5147–5152.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol. 2009;27(17):2831–2837.
   PubMed Web of Science ®Google Scholar
• Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. Jama. 2006;295(17):2057–2071.
   PubMed Web of Science ®Google Scholar
• Dodin S, Blanchet C, Marc I, et al. Acupuncture for menopausal hot flushes. Cochrane Database Syst Rev. 2013;7:CD007410.
   PubMedGoogle Scholar
• Mao JJ, Bowman MA, Xie SX, et al. Electroacupuncture versus gabapentin for hot flashes among breast cancer survivors: a randomized placebo-controlled trial. J Clin Oncol. 2015;33(31):3615–3620.
   PubMed Web of Science ®Google Scholar
• Presant CA, Bosserman L, Young T, et al. Aromatase inhibitor–associated arthralgia and/or bone pain: frequency and characterization in non–clinical trial patients. Clin Breast Cancer. 2007;7(10):775–778.
   PubMed Web of Science ®Google Scholar
• Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877–3883.
   PubMed Web of Science ®Google Scholar
• Fontaine C, Meulemans A, Huizing M, et al. Tolerance of adjuvant letrozole outside of clinical trials. Breast. 2008;17(4):376–381.
   PubMed Web of Science ®Google Scholar
• Henry NL, Giles JT, Ang D, et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat. 2008;111(2):365–372.
   PubMed Web of Science ®Google Scholar
• Henry NL, Azzouz F, Desta Z, et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol. 2012;30(9):936–942.
   PubMed Web of Science ®Google Scholar
• Morales L, Pans S, Verschueren K, et al. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor–associated arthralgia syndrome. J Clin Oncol. 2008;26(19):3147–3152.
   PubMed Web of Science ®Google Scholar
• Irwin ML, Cartmel B, Gross C, et al. Randomized exercise trial of aromatase inhibitor–induced arthralgia in breast cancer survivors. J Clin Oncol. 2014;33(10):1104–1111.
   Google Scholar
• Henry NL, Banerjee M, Wicha M, et al. Pilot study of duloxetine for treatment of aromatase inhibitor‐associated musculoskeletal symptoms. Cancer. 2011;117(24):5469–5475.
   PubMed Web of Science ®Google Scholar
• Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21(21):4042–4057.
   PubMed Web of Science ®Google Scholar
• Brufsky AM, Harker WG, Beck JT, et al. Final 5-year results of Z-FAST trial. Cancer. 2012;118(5):1192–1201.
   PubMed Web of Science ®Google Scholar
• Llombart A, Frassoldati A, Paija O, et al. Immediate administration of zoledronic acid reduces aromatase inhibitor–associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer. 2012;12(1):40–48.
   PubMed Web of Science ®Google Scholar
• Chin SN, Trinkaus M, Simmons C, et al. Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer. Clin Breast Cancer. 2009;9(2):108–117.
   PubMed Web of Science ®Google Scholar
• Wills S, Ravipati A, Venuturumilli P, et al. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract. 2012;8(3):144–148.
   PubMedGoogle Scholar